<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151299">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01832389</url>
  </required_header>
  <id_info>
    <org_study_id>PiSAH</org_study_id>
    <nct_id>NCT01832389</nct_id>
  </id_info>
  <brief_title>Goal Directed Therapy After Aneurysmal Subarachnoid Haemorrhage</brief_title>
  <acronym>PiSAH</acronym>
  <official_title>Does a PiCCO-controlled Advanced Haemodynamic Monitoring Improve the Outcome After Aneurysmal Subarachnoid Haemorrhage?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether a goal-directed therapy can reduce the
      incidence of delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aneurysmal subarachnoid haemorrhage (SAH) is a frequent and dangerous worldwide cause
      for stroke. A typical complication presents delayed cerebral ischemia as a consequence of
      cerebral vasospasms, which occurs in 46% of the cases. The Triple-H-therapy (Hypervolaemia,
      Hypertension and Haemodilution) was favoured to prevent ischaemic complications after
      vasospasm for a long time. However recently, the focus is mainly on hypertension, and it is
      recommended to maintain normovolaemia. The debate how to assure normovolaemia is still on
      going, therefore, this study was designed to examine whether a PiCCO-controlled haemodynamic
      monitoring and a goal-directed therapy can reduce the incidence of delayed cerebral
      ischaemia after SAH.

      The present study is a prospective randomized controlled clinical study. Patients older than
      18 years with an aneurysmal SAH will be enrolled. They will be divided into two groups: a
      control group &quot;C&quot; and a PiCCO group &quot;P&quot;. Both groups will be treated according to the
      current guidelines. In addition, in group P the volume and catecholamine therapy will be
      controlled by means of PiCCO-controlled monitoring and an algorithm.

      The primary end point is the number of occurred delayed cerebral ischaemia per patient.
      Secondary end points are neurological, pulmonary, cardiovascular, renal, and hepatic
      complications as well as electrolyte and serum glucose disturbance, sepsis, and mortality,
      length of hospital and intensive care unit stay and the amount of volume and catecholamines
      administered.

      All participants are to be contacted three months after discharge, and their health status
      is to be determined by using the GOS (Glasgow Outcome Scale).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>number of occurred delayed cerebral ischaemia (DCI) per patient</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>a 2 point increase in the score of the NIHSS-scale lasting for at least 8 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pulmonary and cardiovascular complications</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurological complications</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal and hepatic complications</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electrolyte and serum glucose disturbance</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sepsis, and mortality</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital and intensive care unit stay</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of volume and catecholamines administered</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Aneurysmal Subarachnoid Haemorrhage</condition>
  <condition>SAH</condition>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PiCCO-controlled group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PiCCO</intervention_name>
    <arm_group_label>Group P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aneurysmal Subarachnoid Haemorrhage (SAH)

          -  Age ≥ 18 years

        Exclusion Criteria:

          -  traumatic SAH

          -  congestive heart failure

          -  severe diseases of aorta or aortic valve

          -  pregnancy

          -  calcium antagonist intolerance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bettina Jungwirth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Anaesthesiologie, Klinikum rechts der Isar der Technischen Universität München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bettina Jungwirth, MD</last_name>
    <phone>+49 89 4140</phone>
    <phone_ext>4291</phone_ext>
    <email>b.jungwirth@lrz.tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aida Anetsberger, MD</last_name>
    <phone>+49 89 4140</phone>
    <phone_ext>4291</phone_ext>
    <email>a.anetsberger@lrz.tum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik für Anaesthesiologie, Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Jungwirth, MD</last_name>
      <phone>49 89 4140</phone>
      <phone_ext>4291</phone_ext>
      <email>b.jungwirth@lrz.tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Aida Anetsberger, MD</last_name>
      <phone>49 89 4140</phone>
      <phone_ext>4291</phone_ext>
      <email>a.anetsberger@lrz.tum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Bettina Jungwirth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aida Anetsberger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ralph Bogdanski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Martin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med. 2006 Jan 26;354(4):387-96. Review. No abstract available.</citation>
    <PMID>16436770</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 11, 2013</lastchanged_date>
  <firstreceived_date>October 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subarachnoid Haemorrhage (SAH)</keyword>
  <keyword>vasospasm</keyword>
  <keyword>delayed cerebral ischaemia (DCI)</keyword>
  <keyword>goal directed therapy (GDT)</keyword>
  <keyword>Pulse Contour Cardiac Output (PiCCO)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
